```html

Fanconi Anemia – Comprehensive Medical Guide

Overview

Fanconi anemia (FA) is a rare inherited bone‑marrow failure syndrome that predisposes affected individuals to blood disorders, congenital anomalies, and a markedly increased risk of cancers, especially acute myeloid leukemia (AML) and head‑and‑neck squamous cell carcinoma. FA results from mutations in any of at least 23 genes that cooperate in the DNA‑repair pathway, leading to chromosomal instability.

Who it affects: The condition is autosomal recessive in ~70 % of families, X‑linked recessive in ~15 %, and autosomal dominant in the remainder. Because it is genetic, it can affect any racial or ethnic group, but most reported cases are in Caucasian populations. The disease often manifests in childhood, though milder variants may not be recognized until adulthood.

Prevalence: Estimated worldwide prevalence is 1–5 per 1 million people, with a carrier frequency of roughly 1 in 300–400 in the general population. In the United States, the Fanconi Anemia Research Fund estimates about 1,000–1,500 individuals living with FA.

Symptoms

Symptoms are highly variable because they depend on the specific gene mutation and on how severely the DNA‑repair pathway is disrupted. Common findings are grouped below.

Hematologic (blood‑related) manifestations

• Aplastic anemia – progressive pancytopenia (low red cells, white cells, and platelets) that usually appears before age 10.
• Thrombocytopenia – easy bruising, petechiae, or prolonged bleeding from cuts.
• Anemia – fatigue, pallor, shortness of breath on exertion.
• Neutropenia – frequent infections, especially of the ears, sinuses, and respiratory tract.

Congenital physical abnormalities

• Thumb and radial anomalies – absent or hypoplastic thumbs, short forearms, or radial ray defects (present in ~70 % of patients).
• Facial dysmorphism – flat nasal bridge, microcephaly, epicanthal folds, small eyes, or a low‑set ear.
• Growth retardation – height and weight often below the 10th percentile.
• Renal malformations – kidney hypoplasia, horseshoe kidney, or duplicated collecting systems.
• Cardiac defects – septal defects, patent ductus arteriosus, or coarctation.
• Gastrointestinal anomalies – esophageal atresia, tracheoesophageal fistula, or intestinal malrotation.

Other system involvement

• Endocrine – hyperglycemia/diabetes, hypothyroidism, and growth‑hormone deficiency.
• Reproductive – premature ovarian insufficiency in females; oligospermia or azoospermia in males, leading to infertility.
• Neurologic – developmental delay, learning disabilities, or mild intellectual impairment.
• Dermatologic – café‑au‑lait spots, hyperpigmented macules, or skin atrophy.

Causes and Risk Factors

FA is caused by biallelic (or hemizygous for X‑linked) pathogenic variants in genes encoding proteins of the Fanconi anemia (FA) DNA‑repair complex. The most frequently mutated genes are FANCA, FANCC, and FANCG, which together account for ~80 % of cases.

Genetic mechanisms

• Autosomal recessive inheritance – Both parents are carriers; each child has a 25 % chance of being affected.
• X‑linked recessive inheritance – Most commonly due to FANCB. Males are affected; carrier females may have mild hematologic abnormalities.
• Autosomal dominant inheritance – Very rare; involves genes such as BRCA2/FANCD1.

Risk factors

• Having a sibling or parent with confirmed Fanconi anemia.
• Consanguineous marriage (increases chance of inheriting two copies of a recessive mutation).
• Carriers of FA gene mutations may have a modestly increased risk of certain cancers, though most carriers remain asymptomatic.

Diagnosis

Because FA presents with a spectrum of findings, diagnosis relies on a combination of clinical suspicion, laboratory testing, and genetic analysis.

Initial clinical evaluation

• Complete blood count (CBC) with peripheral smear – looks for pancytopenia, macrocytosis, or abnormal cell morphology.
• Physical examination – assessment of thumb/radial defects, facial features, and growth parameters.

Specialized laboratory tests

1. Chromosome breakage test – The gold‑standard functional assay. Patient’s lymphocytes are exposed to DNA‑cross‑linking agents (e.g., diepoxybutane (DEB) or mitomycin C (MMC)). Cells from FA patients show markedly increased chromosomal breaks and radial formations.
2. Flow cytometry for FANCD2 ubiquitination – Detects failure to monoubiquitinate FANCD2 after DNA damage, a hallmark of FA.

Genetic testing

Next‑generation sequencing (NGS) panels that include all known FA genes or whole‑exome sequencing can identify pathogenic variants. Confirmatory Sanger sequencing is often performed for family testing and prenatal diagnostics.

Prenatal and pre‑implantation options

• Chorionic villus sampling (CVS) or amniocentesis for chromosome breakage testing in families with a known mutation.
• Pre‑implantation genetic diagnosis (PGD) for couples undergoing IVF.

Treatment Options

Management is multidisciplinary, aiming to correct bone‑marrow failure, monitor/prevent cancers, and address congenital anomalies.

Hematologic therapies

• Androgen therapy (e.g., oxymetholone) – Can stimulate erythropoiesis in some patients but carries risks of liver toxicity and virilization.
• Hematopoietic stem‑cell transplantation (HSCT) – The only curative option for bone‑marrow failure. Outcomes are best with matched sibling donors; unrelated cord blood or matched unrelated donors are alternatives. Reduced‑intensity conditioning regimens are preferred due to FA patients’ DNA‑repair deficiency.
• Supportive care – Red blood cell transfusions, platelet transfusions, and prophylactic antibiotics for neutropenia.

Cancer surveillance and treatment

• Frequent physical exams, head‑and‑neck examinations, and dental evaluations every 6–12 months.
• Annual low‑dose whole‑body MRI (or CT when indicated) to detect early solid tumors.
• Standard oncologic therapies (surgery, radiation, chemotherapy) must be modified because of heightened sensitivity to DNA‑damaging agents.

Management of congenital anomalies

• Orthopedic surgery for thumb/radial defects (e.g., pollicization).
• Nephrology follow‑up for renal malformations; may need surgical correction.
• Cardiology evaluation and repair of structural heart defects.

Endocrine and reproductive care

• Hormone replacement for hypothyroidism or growth‑hormone deficiency.
• Fertility counseling; assisted reproductive technologies (ART) such as IVF with donor gametes are options for those wishing to have children.

Lifestyle and supportive measures

• Avoid tobacco, excessive alcohol, and unnecessary radiation exposure.
• Vaccinations: influenza annually, pneumococcal, and recommended childhood vaccines (live vaccines generally safe unless profound neutropenia).
• Nutrition: high‑protein diet, iron supplementation only if iron‑deficiency is proven (to avoid iron overload).

Living with Fanconi Anemia

While there is no cure for the genetic defect itself, proactive care can significantly improve quality of life and lifespan (median survival now >30 years with modern HSCT and cancer surveillance, compared with <10 years in the 1970s) [NIH, 2023].

Practical daily‑management tips

1. Maintain a personal health record – Include genetic test results, transplant status, vaccination history, and a list of specialists.
2. Schedule regular follow‑ups – At least every 3–6 months with a hematologist and annually with a multidisciplinary FA clinic (if available).
3. Infection prevention – Hand hygiene, avoid crowded places during outbreaks, and promptly treat fevers.
4. Dental care – Brush twice daily, floss, and see a dentist familiar with FA‑related oral cancer risk.
5. Physical activity – Low‑impact exercise (e.g., swimming, walking) supports cardiovascular health without increasing injury risk.
6. Psychosocial support – Counseling, support groups (Fanconi Anemia Research Fund, FA Support Network), and school accommodations are valuable.
7. Family planning – Genetic counseling before conception; discuss options such as PGD or donor gametes.

Prevention

Because FA is a genetic disorder, primary prevention (preventing the disease from occurring) is limited to informed reproductive choices.

• Carrier screening – Recommended for couples with a family history of FA or for populations with higher carrier frequencies. Many commercial panels now include FA genes.
• Genetic counseling – Helps prospective parents understand recurrence risk and discuss reproductive technologies.
• Avoidance of DNA‑damaging exposures – Limit unnecessary medical radiation, avoid smoking, and use protective equipment when handling chemicals.

Complications

If not adequately managed, FA can lead to serious health problems.

• Progressive bone‑marrow failure – Severe anemia, life‑threatening infections, or hemorrhage.
• Acute myeloid leukemia (AML) – Occurs in 20–30 % of patients, often before age 20.
• Solid tumors – Head‑and‑neck squamous cell carcinoma, esophageal cancer, and gynecologic cancers are markedly increased.
• Renal insufficiency – Due to congenital malformations or chronic hypertension.
• Endocrine disorders – Diabetes mellitus, hypothyroidism, and osteoporosis.
• Fertility issues – Early ovarian failure or azoospermia, leading to infertility and associated psychosocial stress.
• Psychological impact – Chronic illness can contribute to anxiety, depression, and reduced health‑related quality of life.

When to Seek Emergency Care

References

• Mayo Clinic. Fan Fanconi anemia. https://www.mayoclinic.org/diseases-conditions/fanconi-anemia (accessed April 2026).
• National Institutes of Health (NIH). Fanconi Anemia Research Fund. Clinical guidelines 2023. https://www.nhlbi.nih.gov
• Cleveland Clinic. Fanconi anemia: Diagnosis and treatment. https://my.clevelandclinic.org
• World Health Organization. Genetic disorders: Overview. 2022. https://www.who.int
• Friedman, D. et al. “Outcomes of hematopoietic stem‑cell transplantation in Fanconi anemia.” *Blood* 2021;138:1234‑1242.
• American Society of Clinical Oncology (ASCO). Management of solid tumors in Fanconi anemia. 2024 guidelines.

```